CF
ITOS

Corebridge Financial’s iTeos Therapeutics ITOS Stock Holding History

Corebridge Financial’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,036
Closed -$77.8K – 1374
2025
Q1 		$77.8K Sell
13,036
-194
-1% -$1.42K ﹤0.01% 2569
2024
Q4 		$102K Sell
13,230
-998
-7% -$8.57K ﹤0.01% 2545
2024
Q3 		$145K Buy
14,228
+262
+2% +$4K ﹤0.01% 2407
2024
Q2 		$207K Buy
+13,966
New +$200K ﹤0.01% 2174

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Corebridge Financial's ITOS Position: Q2 2025 in Review

Corebridge Financial sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 13,036 shares — an estimated $77.8K sold.

Corebridge Financial first reported a position in ITOS in Q2 2024 and held it in 4 quarters. The position peaked at $207K in Q2 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Corebridge Financial reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 13,036 iTeos Therapeutics shares in Q2 2025, an estimated $77.8K.
  • Corebridge Financial first reported a position in iTeos Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's iTeos Therapeutics position peaked at $207K in Q2 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.